MedEsthetics

AUGUST 21, 2024

Pelage Pharmaceuticals announced the commencement of the Phase 2a trial for PP405, a novel hair loss treatment targeting dormant follicle stem cells.

Pharmaceutical 145

Pharmaceutical Treatments Clinic 145

Dermatology Times

APRIL 27, 2024

Keep up with the latest headlines in dermatology from the past week, including the appointment of All Detergent's first chief dermatology advisor, Incyte's acquisition of Escient Pharmaceuticals, and more.

Pharmaceutical 74

Pharmaceutical Dermatology 74

Dermatology Times

AUGUST 14, 2024

Myron Czuczman, MD, of Citius Pharmaceuticals recently shared perspectives on the role and potential of Lymphir in CTCL.

Pharmaceutical 71

Pharmaceutical 71

Dermatology Times

OCTOBER 3, 2024

This expert review explores the multifaceted causes of female hair loss—hormonal imbalances, inflammation, nutrient deficiencies, aging, and oxidative stress—and explores non-pharmaceutical interventions

Pharmaceutical 45

Pharmaceutical 45

Dermatology Times

JANUARY 26, 2024

ICYMI, this week we had news about the completion of LEO Pharma's acquisition of Timber Pharmaceuticals, research pointing to melanoma overdiagnosis in White patients, artificial intelligence in skin cancer detection, and more.

Pharmaceutical 78

Pharmaceutical 78

The Dermatology Digest

AUGUST 21, 2024

Food and Drug Administration, according to Leo Pharma and Timber Pharmaceuticals. LEO Pharma acquired TMB-001 from Timber Pharmaceuticals in January 2024 following Timber’s Chapter 11 bankruptcy filing. As a consequence of the acquisition, Timber Pharmaceuticals was reformed as a fully owned subsidiary of LEO Pharma.

Pharmaceutical 36

Pharmaceutical Clinic Office Safety 36

Dermatology Times

FEBRUARY 29, 2024

The collaboration with Sato marks a continued effort of Arcutis to collaborate with pharmaceutical companies and license topical roflumilast in Asia.

Pharmaceutical 73

Pharmaceutical 73

Dermatology Times

MAY 7, 2024

ASLAN Pharmaceuticals presented new data this morning, including a 90% EASI score reduction.

Pharmaceutical 74

Pharmaceutical 74

Dermatology Times

JUNE 21, 2024

Botanix Pharmaceuticals announced the approval of its sofpironium topical gel, 12.45% for adults and children ages 9 and older.

Pharmaceutical 62

Pharmaceutical 62

The Dermatology Digest

MAY 15, 2024

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. FDA and Japan’s Pharmaceuticals and Medical Device Agency (PMDA) on the proposed design of the Phase 3 clinical trial. With a prevalence of approximately 22 million patients in the U.S.

Pharmaceutical 36

Pharmaceutical Clinic Sales Dermatology 36

Dermatology Times

AUGUST 26, 2023

Keep up with the latest headlines in dermatology from the past week, including growing concerns of a dermatologist shortage in Ontario, LEO Pharma's acquisition of Timber Pharmaceuticals, and more. This week, we have also included a patient-forward rundown of top headlines to share with your patients.

Pharmaceutical 69

Pharmaceutical Dermatology 69

The Dermatology Digest

NOVEMBER 5, 2024

Sun Pharma acquired deuruxolitinib when it purchased Concert Pharmaceuticals in March 2023 and received the U.S, Deuruxolitinib is a deuterated form of ruxolitinib. In the lawsuit, Incyte states that the patent covers claims on deuterated forms of the compound. The post Patent Dispute Update: Incyte Blocks U.S.

Pharmaceutical 36

Pharmaceutical Dermatitis Dermatology 36

The Dermatology Digest

APRIL 11, 2024

The first patient has been treated in Stamford Pharmaceuticals Inc.’s We believe there is an opportunity to further improve patient benefit in locally advanced BCC patients based on the current standard of care,” says Clement Leong, PhD, CEO of Stamford Pharmaceuticals, in a news release.

Pharmaceutical 36

Pharmaceutical Clinic Injections Dermatology 36

Dermatology Times

DECEMBER 19, 2023

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options.

Pharmaceutical 36

Pharmaceutical Dermatitis Therapy 36

The Dermatology Digest

SEPTEMBER 12, 2024

In 2011, Mr. Clark co-founded and served as President and CEO of Clark Pharmaceuticals, where he launched and sold several more over-the-counter dermatology products. His passing is a true loss to the dermatology world, as his contributions helped treat millions of people with skin diseases.

Dermatology 74

Dermatology Pharmaceutical Skincare 74

The Dermatology Digest

JANUARY 29, 2024

Medicaid and Medicare patient populations,” says Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, in a news release. “In “By securing a permanent J-Code for YCANTH, we have successfully reached a critical milestone in our commercial strategy that we expect will help us accelerate YCANTH utilization among the U.S.

Pharmaceutical 74

Pharmaceutical Office Medical Management 74

The Dermatology Digest

FEBRUARY 16, 2024

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

Dermatology Times

OCTOBER 17, 2023

Hilary Baldwin, MD, offers her insights and hypotheses regarding the future of over-the-counter and pharmaceutical treatments, emphasizing the evolving landscape and the potential role of targeted microbiome-based approaches in the management of acne.

Pharmaceutical 36

Pharmaceutical Skincare Management Treatments 36

The Dermatology Digest

JULY 5, 2024

Recently, Almirall was rated as one of the top 5% of companies in the pharmaceutical industry by Sustainalytics. Ecovadis recognized Almirall with a platinum medal, placing it in the top 1% of evaluated pharmaceutical companies for sustainability.

Sustainability 36

Sustainability Pharmaceutical Portfolios Management 36

Dermatology Times

DECEMBER 18, 2023

Emphasizing the challenges of the steroid treatment cycle, the expert provides insights into integrating parental preferences for "natural" agents alongside effective pharmaceutical options. An expert in skin condition management discusses the case of a 13-year-old male with a prolonged history of AD and early-onset food allergies.

Pharmaceutical 36

Pharmaceutical Management Treatments 36

Renee Rouleau

JANUARY 19, 2024

Pharmaceutical and Medical Advancements Ingredients that have been traditionally used for non-skincare purposes are now finding their way into the beauty industry. For example, witch hazel , previously used in wound healing and as a vasoconstrictor in modern medicine, is now used for soothing the skin and reducing excess oil production.

Skincare 195

Skincare Innovations Ingredients Oily Skin 195

The Dermatology Digest

JANUARY 5, 2024

Zelsuvmi is expected to be commercially available during the second half of 2024, according to Ligand Pharmaceuticals. Approved in 2023 Verrica Pharmaceuticals’ Ycanth (cantharidin) was the first U.S.-approved Ligand Pharmaceuticals acquired all the assets of Novan, Inc. in September 2023. Novan developed Zelsuvmi.

Pharmaceutical 36

Pharmaceutical Office Medical Dermatology 36

Aesthetics Advisor

AUGUST 16, 2023

Novo traded at fresh highs as the Danish pharmaceutical company gained ground on the only European megacap that is larger than it. Makers of syringes for the pharmaceutical industry, Stevanato Group SpA and West Pharmaceutical Services Inc., also gained — rising 9.0% respectively.

Sales 36

Sales Pharmaceutical Marketing Medical 36

Aesthetics Advisor

AUGUST 22, 2023

The pharmaceutical industry doesn’t generate its desired profits by creating common drugs, even though they’re in high demand. In February, Akorn Pharmaceuticals, a company dedicated to producing generic drugs, filed for bankruptcy and had to close all its U.S. What produces higher profits are newer drugs , according to the U.S.

Pharmaceutical 36

Pharmaceutical Hospital Document Medical 36

The Dermatology Digest

JANUARY 5, 2024

The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. VP-315 is a chemotherapeutic administered intratumorally.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

JANUARY 4, 2024

Joint development for DMB-3115 was initiated in 2013 by Dong-A Socio Holdings and Meiji Seika Pharma, with exclusive commercialization rights granted to Intas Pharmaceuticals through a partnership announced in 2021. As a global subsidiary of Intas Pharmaceuticals, Accord BioPharma will be responsible for U.S. commercialization.

Pharmaceutical 36

Pharmaceutical Partnerships Clinic Safety 36

The Eco Well Blog

OCTOBER 17, 2024

E.g. We've been trying for decades to get a viable male birth control pharmaceutical, and still haven’t been successful. These assays are very sensitive to try to find e.g. potential birth control options, which it turns out, is pretty dang hard. Do cosmetics cause endocrine disruption? Realistically, probably not.

Pharmaceutical 52

Pharmaceutical Ingredients 52

The Dermatology Digest

FEBRUARY 5, 2024

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising, Unfair Competition Verrica Pharmaceuticals Inc. has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories Inc.,

Dermatology 36

Dermatology Pharmaceutical Technology Sales 36

The Dermatology Digest

FEBRUARY 8, 2024

Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Food and Drug Administration (FDA) recently OKed a label update for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Immunotherapy including cemiplimab (Libtayo, Regeneron Pharmaceuticals) has also brought hope to even the most difficult tumors,” he says.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

AUGUST 6, 2024

Food and Drug Administration (FDA) and the Pharmaceuticals and Medical Devices Agency in Japan. Regulatory applications for the 320mg bimekizumab in a volume of 2mL device are currently in review with the U.S. The post European Commission Approves 320mg Syringes and Pens of UCB’s Bimekizumab appeared first on The Dermatology Digest.

Injections 36

Injections Pharmaceutical Marketing Dermatology 36

The Dermatology Digest

JUNE 13, 2024

Mr. Høiland has more than 25 years of experience in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US). He will succeed Tord Lendau. “He will bring valuable insights and experience especially from the US market, which is our primary focus.

Partnerships 36

Partnerships Pharmaceutical Marketing Dermatology 36

Aesthetics Advisor

NOVEMBER 5, 2023

Brands like Centrum, Nature Made, and One-A-Day have also been enveloped by global giants like Glaxo Smith Kline, Otsuka Pharmaceuticals, and Bayer. The motivation becomes even murkier when these pharmaceutical behemoths, like Bayer, also have stakes in sectors such as agricultural chemicals. Moreover, it's not just Nestlé.

Pharmaceutical 36

Pharmaceutical Portfolios Branding Extractions 36

The Dermatology Digest

JULY 22, 2024

Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. Launches in further European countries are scheduled over the coming months, following national price approvals, via a fully European supply chain.

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

Aesthetics Advisor

JANUARY 18, 2024

Currently there are three main categories of pharmaceutical agents used to treat or prevent ischemia issues: thrombolytics, antiplatelets, and anticoagulants. Is there not a safer and also effective natural option for helping patients besides the above categories of pharmaceuticals?

Pharmaceutical 36

Pharmaceutical Extractions Clinic Safety 36

The Dermatology Digest

NOVEMBER 6, 2024

PeDRA thanks AbbVie and Sanofi & Regeneron Pharmaceuticals for their support of 2024 EIRGs. Awardees received a budget to cover project and living expenses and a stipend to attend the 2024 PeDRA Annual Conference. The post PeDRA Launches Two New Grant Programs, Announces 2024 EIRG Recipients appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Hospital Dermatology Medical 36

The Dermatology Digest

MARCH 28, 2024

Mr. Cotton currently serves on the board of directors of Eisai Pharmaceutical U.S., a research and development pharmaceutical company and subsidiary of Eisai Company, Ltd., Cotton received The Sagamore of the Wabash Award, one of the highest Indiana State honors from Indiana Governor Eric J.

Pharmaceutical 28

Pharmaceutical Technology Networking Office 28

The Dermatology Digest

MAY 14, 2024

TDD Talks to Brian Hilberdink, LEO Pharma’s EVP of North America, About Congenital Ichthyosis LEO Pharma recently acquired TMB-001 and other assets from Timber Pharmaceuticals following Timber’s Chapter 11 bankruptcy filing. Topical isotretinoin, even when applied to 90% of a patient’s body surface area, showed minimal systemic absorption.

Pharmaceutical 36

Pharmaceutical Skin Types Dermatology Therapy 36